Christopher J. O'Connell
Chairman and Chief Executive Officer, Waters Corporation
Linda Baddour
Executive Vice President, PRA Health Sciences Inc.
Dr. Michael J. Berendt
Independent Director and Investor
Edward Conard
Independent Director and Investor
Laurie H. Glimcher, M.D.
President and Chief Executive Officer of the Dana-Farber Cancer Institute,
Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center and
Richard and Susan Smith Professor of Medicine
Gary Hendrickson
Retired Chairman, President and CEO, Valspar Corporation
Christopher A. Kuebler
Retired Chairman and Chief Executive Officer, Covance Inc.
Flemming Ornskov
Chief Executive Officer, Shire plc
JoAnn A. Reed
Independent Director and Investor
Thomas P. Salice
Managing Member, SFW Capital Partners, LLC
Christopher J. O'Connell was appointed as President, Chief Executive Officer and a member the Board of Directors for Waters Corporation in September, 2015. He was subsequently elected Chairman of the Board effective January 2018. Previously, Mr. O'Connell served at Medtronic plc for twenty-one years, most recently as Executive Vice President and President of its Restorative Therapies Group, with global responsibility for the company’s Spine & Biologics, Neuromodulation, Surgical Technologies, Neurovascular and Orthopedics business units. He was a member of Medtronic’s Executive Committee for nine years, and a Corporate Officer. O’Connell joined Medtronic in 1994 and held senior leadership positions in multiple business units and corporate functions. He started his career at Chemical Banking Corporation. O'Connell earned a Bachelor’s degree from Northwestern University in 1989 and a Master’s degree in Business Administration from Harvard University in 1994.
Linda Baddour has served as Executive Vice President and CFO of PRA Health Sciences since 2007. Previously, she was the CFO at Pharmaceutical Product Development, Inc., where she also managed the company's M&A and information technology strategies. Prior to being named CFO at PPD, she was Treasurer and Chief Accounting Officer. Ms. Baddour earned both her bachelor's degree and her MBA from the University of North Carolina at Wilmington. She is also a certified public accountant.
Michael J. Berendt, Ph.D. has served as a Director of the Company since March 1998. Dr. Berendt is the President and Chief Executive Officer of Aegera Therapeutics Inc., a position he assumed in March 2006. From August 2004 to December 2005, Dr. Berendt served as Managing Director of Research Corporation Technologies. From November 2000 to August 2004, Dr. Berendt served as Managing Director of AEA Investors. Dr. Berendt also worked for 18 years, from 1982 to 2000, in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporation, and a Group Director of Drug Discovery at Pfizer, Inc. Dr. Berendt has served as a director of Onyx Pharmaceuticals, Myriad Genetics, Inc., Catalyst Biosciences and Northstar Neuroscience.
Edward Conard has served as a Director of the Company since August 1994. Mr. Conard is an independent director and investor. He was a Managing Director of Bain Capital, LLC from March 1993 to December 31, 2007. Mr. Conard was previously a Director of Wasserstein Perella and Company, an investment banking firm that specializes in mergers and acquisitions, and a Vice President of Bain & Company heading up the firm’s operations practice area. Mr. Conard is the author of two top ten New York Times bestselling books: The Upside of Inequality: How Good Intentions Undermine the Middle Class (2016) and Unintended Consequences: Why Everything You’ve Been Told About the Economy Is Wrong (2012). He is a visiting scholar at the American Enterprise Institute. He has written opinion pieces for a variety of publications including: The Wall Street Journal, New York Times, Washington Post, Time, Foreign Affairs, National Review, Harvard Business Review, and Fortune.
Dr. Laurie H. Glimcher has served as a Director of the Company since January 1998. Dr. Glimcher is the President and Chief Executive Officer of the Dana-Farber Cancer Institute, the Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine, Harvard Medical School. From January 2012 to June 2016, Dr. Glimcher served as the Stephen and Suzanne Weiss Dean of the Weill Cornell Medical College and Provost for Medical Affairs of Cornell University. From 1991 through 2011, Dr. Glimcher served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School.
Gary Hendrickson was the Chairman of the Valspar Corporation between 2012 and 2017, and CEO since 2011. Prior to being named as CEO, Mr. Hendrickson served Valspar as Chief Operating Officer, President of multiple business units, and Corporate Vice President and President of Asia Pacific. Before joining Valspar, Mr. Hendrickson served for 11 years in the U.S. Navy as a Surface Warfare Officer, achieving the rank of Lieutenant Commander. He is currently Chairman of the Board at CPG International LLC and an independent Director of Polaris Industries Inc. Mr. Hendrickson earned his bachelor's degree from University of Connecticut and his MBA from Harvard University.
Christopher A. Kuebler has served as a Director of the Company since May 2006. Mr. Kuebler served as Chairman and CEO of Covance Inc., and its predecessor companies from November 1994 to December 2004. He served as Chairman during 2005. Prior to joining Covance, Mr. Kuebler spent nearly 20 years in the pharmaceutical industry, at Abbott Laboratories, Squibb Inc. and Monsanto Health Care. Mr. Kuebler is a director of Nektar Therapeutics.
Flemming Ornskov has served as a Director of the Company since June 2017. Dr. Ornskov was appointed Chief Executive Officer of Shire plc in April, 2013, where he serves as Chairman of the Executive Committee, and is a member of the Board of Directors. Dr. Ornskov brings broad operational and medical knowledge, and extensive international, strategic and operational experience in the pharmaceutical sector. Prior to Shire, Dr. Ornskov held key executive leadership positions at Bayer, Bausch & Lomb, Inc., Merck & Co., Inc. and Novartis AG. Dr. Ornskov received his MD from the University of Copenhagen, his MBA from INSEAD, and his Master of Public Health from Harvard University. Before his business career, Dr. Ornskov, trained as an intern and resident in pediatrics at the University Hospital of Copenhagen.
JoAnn A. Reed has served as a Director of the Company since May 2006. Ms. Reed has been a health care services consultant since 2010. From April 2008 to April 2009, she was an advisor to the Chief Executive Officer of Medco Health Solutions, Inc. From 2002 to March 2008, Ms. Reed served as Senior Vice President, Finance and Chief Financial Officer of Medco Health Solutions, Inc. From 1992 to 2002, she served as Senior Vice President, Finance of Medco Health Solutions, Inc. She joined Medco Containment Services, Inc. in 1988. Her prior experience includes employment with CBS, Inc., Aetna/American Re-insurance Co., Standard and Poor’s Financial Services LLC, and Unisys/Timeplex.
Thomas P. Salice has served as a Director of the Company since July 1994. Mr. Salice is a Managing Member of SFW Capital Partners, LLC, a position he assumed in January 2005. From June 1989 to December 2004 Mr. Salice served in a variety of capacities with AEA Investors, Inc. including Managing Director, President and Chief Executive Officer and most recently as Vice-Chairman from October 2002 through 2004. Mr. Salice is a Director of Mettler-Toledo International, Inc.
Officers of the Company are elected annually by the Board of Directors and hold office at the discretion of the Board of Directors. The following persons serve as executive officers of the Company:
Christopher J. O’Connell
Chairman and Chief Executive Officer, Waters Corporation
Keeley A. Aleman
Senior Vice President, General Counsel and Corporate Secretary
Robert G. Carson
Senior Vice President, Corporate Development
Sherry L. Buck
Senior Vice President and Chief Financial Officer
Dr. Michael C. Harrington
Senior Vice President, Global Markets
Francis S. Kim
Senior Vice President, Global Operations
Ian S. King
Senior Vice President, Global Products
Jonathan M. Pratt
Senior Vice President and President of TA Instruments
Elizabeth B. Rae
Senior Vice President, Global Human Resources
Christopher J. O'Connell was appointed as President, Chief Executive Officer and a member the Board of Directors for Waters Corporation in September, 2015. He was subsequently elected Chairman of the Board effective January 2018. Previously, Mr. O'Connell served at Medtronic plc for twenty-one years, most recently as Executive Vice President and President of its Restorative Therapies Group, with global responsibility for the company’s Spine & Biologics, Neuromodulation, Surgical Technologies, Neurovascular and Orthopedics business units. He was a member of Medtronic’s Executive Committee for nine years, and a Corporate Officer. O’Connell joined Medtronic in 1994 and held senior leadership positions in multiple business units and corporate functions. He started his career at Chemical Banking Corporation. O'Connell earned a Bachelor’s degree from Northwestern University in 1989 and a Master’s degree in Business Administration from Harvard University in 1994.
Keeley A. Aleman was promoted to Senior Vice President, General Counsel and Corporate Secretary on October 1, 2019. Ms. Aleman joined Waters in 2006 as the Assistant General Counsel, she has held legal roles focused on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters. Additionally, she has been an inspirational leader as co-chair of Waters Gender Diversity Network, the company’s first formal diversity engagement initiative fostering a balanced workforce in a supportive environment. Prior to joining Waters, she held corporate associate positions at Goodwin Procter, LLP, and Testa, Hurwitz & Thibeault, LLP. Ms. Aleman holds a Juris Doctorate degree from Boston University School of Law, magna cum laude, and a Bachelor of Arts degree with honors from the University of California at Davis.
Sherry L. Buck was appointed Senior Vice President and Chief Financial Officer in January 2017. Previously, Ms. Buck served as the Vice President, Chief Financial Officer of Libbey Inc. since August 2012. From 1993 to 2012, Ms. Buck held several positions at Whirlpool Corporation, including Vice President, Finance/Chief Financial Officer, Global Product and Enterprise Cost Leadership; Vice President, Finance — US; Vice President, Cost Leadership; Vice President, Finance — International; and Vice President, Business Performance Management.
Robert G. Carson joined Waters Corporation in 2018 as its Senior Vice President, Corporate Development. His background spans general management, marketing, strategy, change leadership and capital markets finance. Prior to becoming a member of the Waters team, he was Vice President & General Manager of Medtronic's pacemaker business and in all spent 16 years at Medtronic including roles within the company's Spine business, Neuro business and Investor Relations group. Rob also worked for four years at Banc of America Securities as an investment banking analyst and associate. He received his bachelor of science from the University of Virginia, and his master of business administration from The Wharton School at the University of Pennsylvania.
Dr. Michael C. Harrington was appointed Senior Vice President, Global Markets in February 2016. Dr. Harrington joined Waters in 1987 and has held several senior positions with Waters, including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations. Prior to joining Waters, Dr. Harrington held senior sales positions at Celsis, Inc.
Francis S. Kim joined Waters in early 2017 after a successful 20 years at Medtronic, where he was Vice President of Quality, Restorative Therapies Group. Prior to that role, he had the position of Vice President of Quality, Regulatory, and Clinical Affairs within the Surgical Technologies Division of Medtronic. His background and deep experience at numerous medical device companies (Pfizer, Baxter Healthcare) represent a wide range of both business and functional experiences including in Operations, Supply Chain, Compliance, Marketing, and Program Management. Mr. Kim holds dual Bachelor of Science degrees in Biology and Chemistry, and a Master’s in Business Administration.
Ian S. King was appointed Senior Vice President, Global Products in February 2016. Mr. King joined Waters in 1982 and previously served as Vice President, Separations Technologies and Vice President and General Manager of Consumable Division, as well as a variety of scientific and management positions in Waters’ international subsidiaries. Prior to joining Waters, Mr. King worked at Edinburgh University as a research scientist.
Jonathan M. Pratt was named Waters Corporation Senior Vice President and President of TA Instruments, on September 3, 2019. Prior to joining Waters, Mr. Pratt was President of Beckman Coulter Life Sciences, where he spearheaded efforts that drove improved operating profit and revenue growth both organically and through acquisitions. Additionally, he held senior positions at Pall Corporation, where he was President of its Food & Beverage, Laboratory and ForteBio businesses. Mr. Pratt holds a BSc in chemistry from the University of Reading, UK and an MBA from New York University’s Stern School of Business.
Elizabeth B. Rae was appointed Senior Vice President, Global Human Resources in February 2016 and was Vice President of Human Resources since October 2005 and Vice President of Worldwide Compensation and Benefits since January 2002. Ms. Rae joined Waters in January 1996 as Director of Worldwide Compensation. Prior to joining Waters, she held senior human resources positions in retail, healthcare and financial services companies.